Summary of key efficacy endpoints.

<p>CI, confidence interval; EOTR, end-of-treatment response; eRVR, extended rapid virologic response; mITT, modified intent-to-treat; RBV, ribavirin; RVR, rapid virologic response; SVR12, sustained virologic response at week 12 post-treatment follow-up; TVR, telaprevir.</p

Patient disposition and reasons for discontinuation.

<p>RBV, ribavirin; TVR, telaprevir.</p

On-treatment safety.

<p>AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; RBV, ribavirin; TVR, telaprevir.</p

Baseline demographic and disease characteristics.

<p>HCV, hepatitis C virus; <i>IL28B</i>, interleukin 28B; RBV, ribavirin; TVR, telaprevir.</p

Subgroup analysis for SVR12.

<p>CI, confidence interval; HCV, hepatitis C virus; <i>IL28B</i>, interleukin 28B; RBV, ribavirin; SVR12, sustained virologic response at week 12 post-treatment follow-up; TVR, telaprevir.</p

Changes from baseline in HBV DNA by post-Week 24 treatment (efficacy population).

<p>Changes from baseline in HBV DNA by post-Week 24 treatment (efficacy population).</p

Patient disposition.

<p>Patient disposition.</p

Week 52 glomerular filtration rate (MDRD) changes, by baseline rate and treatment (efficacy population).

<p>Week 52 glomerular filtration rate (MDRD) changes, by baseline rate and treatment (efficacy population).</p

Most common (≥5%) all-cause adverse events through Week 52 (safety population).

*<p>Intensification patients may have had an event during both the telbivudine only and intensification periods. Overall numbers with an indicated event may therefore be less than the row total.</p><p>doi:10.1371/journal.pone.0054279.t003</p

Demographics and baseline characteristics (efficacy population) according to post-Week 24 treatment.

<p>doi:10.1371/journal.pone.0054279.t001</p